Kim Hwa-ok

Title: Kim Hwa-ok: Innovator in Therapeutic Agent Detection

Introduction

Kim Hwa-ok is a notable inventor based in Lexington, MA (US). She has made significant contributions to the field of therapeutic agent detection, particularly in monitoring adherence to nucleoside reverse transcriptase inhibitor (NRTI) metabolites. Her innovative work has implications for improving patient care in the context of pre-exposure prophylaxis.

Latest Patents

Kim Hwa-ok holds a patent for "Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites." This invention provides novel compounds, reagents, systems, and methods for detecting a metabolite related to an NRTI in a biological sample. The patent outlines the use of these reagents, which include NRTI derivatives, analogs, and conjugates, along with antibodies directed to the same. These innovations are particularly useful for antibody-based methods, such as lateral flow immunoassays and other point-of-care devices.

Career Highlights

Kim is currently employed at OraSure Technologies, Inc., where she continues to advance her research and development efforts. Her work is pivotal in the ongoing fight against diseases that require effective monitoring of therapeutic adherence.

Collaborations

Some of her notable coworkers include Giffin Daughtridge and Keith Kardos, who contribute to her innovative projects and research initiatives.

Conclusion

Kim Hwa-ok's contributions to the field of therapeutic agent detection exemplify the impact of innovation in healthcare. Her patent and ongoing work at OraSure Technologies, Inc. highlight her commitment to improving patient outcomes through advanced detection methods.